ChinaDaily Briefs

Daily Brief China: Prosus NV, CK Hutchison Holdings, Cloud Village, Hang Seng Index, NetEase , JD.com Inc (ADR), Taste Gourmet, Gcl Poly Energy Holdings Limited, Beijing Sinotau International Pharmaceutical Technology, iShares MSCI China ETF and more

In today’s briefing:

  • Prosus Is Elevated Vs. Tencent As The Accretion Trade Unfolds
  • CK Hutchison (1 HK): State of Limbo as Exclusivity Deadline Approaches
  • Netease Cloud Music (9899 HK): Stock Up; Short Interest Up; Global Index Inclusion
  • HSI Index Tactical View: How Much Further Can the Rally Run?
  • Tencent/Netease: Zero Approval in July
  • [JD.com, Inc (JD US, SELL, TP US$24) TP Change]: C2Q25 Preview: Near Term Loss Pressure Imminent
  • Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – July 2025
  • GCL Tech (3800): Why Wait?
  • Sinotau (先通医药) Pre-IPO: A Niche Radiopharmaceutical Player
  • More Breakouts and Risk-On Developments; Monitoring Rotations: Miners, Retail, Lithium, China


Prosus Is Elevated Vs. Tencent As The Accretion Trade Unfolds

By David Blennerhassett

  • Since unwinding the Naspers (NPN SJ)/Prosus (PRX NA) circularity, Prosus has been selling Tencent shares, and buying back its share. Separately, Tencent is buying its shares to offset Prosus’ selling. 
  • Prosus’ stake in Tencent has now edged below 23%, a little over seven months since dipping below 24%.
  • On an implied stub and relative value, Prosus is elevated to Tencent, suggesting an unwinding of the stub.

CK Hutchison (1 HK): State of Limbo as Exclusivity Deadline Approaches

By Arun George

  • The 145-day exclusivity period between CK Hutchison Holdings (1 HK) and the BlackRock-TiL consortium for the politically charged ports deal ends on July 27.
  • The transaction is in limbo as China’s preferred pathway for approval (COSCO is included in the consortium as an equal partner) has several issues.
  • It is equally probable that the deal will be finalised in some shape or form or fall apart. With shares up 31% and nearing a five-year high, take profits. 

Netease Cloud Music (9899 HK): Stock Up; Short Interest Up; Global Index Inclusion

By Brian Freitas


HSI Index Tactical View: How Much Further Can the Rally Run?

By Nico Rosti

  • The Hang Seng Index (HSI INDEX) has reached new highs (25538). Our quantitative model says the index has reached a 75% probability of reversal.
  • Let’s break down the model’s info: PRICE MODEL 75%, TIME MODEL 75%, combined prob. of reversal is 75%. The fact that both model’s factors are overbought is “bearish”.
  • Can the index climb higher? Our detailed analysis is in the insight below, together with screenshots from the model.

Tencent/Netease: Zero Approval in July

By Ke Yan, CFA, FRM

  • China announced game approval for the July batch. The number of games approved remained at a higher level than 2023.
  • The pace of China game approval appears to have accelerated to the same level as pre-tightening.
  • In July, 7 listed companies that we tracked received zero domestic game approval. Having said that, overall sentiment is improving and gaming names have performed well YTD.

[JD.com, Inc (JD US, SELL, TP US$24) TP Change]: C2Q25 Preview: Near Term Loss Pressure Imminent

By Ying Pan

  • We expect JD.com to report C2Q25 revenue/adjusted operating profit growth of 16%/(63%) YoY, which is 2%/(50%) vs. cons. due to the takeout subsidies.
  • Despite the surge in new users, we remain skeptical on the ST effectiveness of food delivery (FD) cross-selling. We expect 2025 FD losses at RMB29bn.
  • We keep JD as SELL and cut TP from US$25 to US$24.


GCL Tech (3800): Why Wait?

By Henry Soediarko

  • Suffering from overcapacity for a while, the company is a beneficiary of the Chinese government policy to consolidate the solar industry. 
  • At 0.6x PBR and a share price at HKD 1.3, far from its high at HKD 4, sounds like a bargain. 
  • Management has conducted one share buy back this year and share price rallied afterwards. 

Sinotau (先通医药) Pre-IPO: A Niche Radiopharmaceutical Player

By Ke Yan, CFA, FRM

  • Sinotau, a China-based clinical-stage biotech, is looking to raise at least USD 100 million via a Hong Kong listing. The book runner is CICC.
  • In this insight, we look at the company’s core products, XTR008, XTR006, XTR004, and XTR003, including its mechanism and clinical data.
  • We also look at the company’s pre-IPO investors and management team.

More Breakouts and Risk-On Developments; Monitoring Rotations: Miners, Retail, Lithium, China

By Joe Jasper

  • We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).
  • Short-Term supports on the SPX include the 20-day MA (currently 6233), 6200, 6100-6150, and 6028-6059, with additional supports at 5804-5854 and 5700-5785. Buy pullbacks to these areas.
  • SPX has not closed below its 20-day MA for two months, but even when it does, all we would expect to happen is for a new, less-steep uptrend to form.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars